Equity Profile

ARQT

Arcutis Biotherapeutics, Inc.

Health CareBiotechnology$3.2B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Arcutis Biotherapeutics, Inc. (ARQT) is a biotechnology company focused on developing innovative treatments for skin diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS indicates the company's profitability and is a key measure of its financial health.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and drive future profits.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ARQT Q2-2026 Earnings Preview

Context

Company Snapshot

Arcutis Biotherapeutics, Inc. (ARQT) is a biotechnology company focused on developing innovative treatments for skin diseases. With a market cap of $3 billion, it operates in the health care sector, addressing significant unmet needs in dermatology.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+19.67%

Avg Stock Reaction

+2.77%

Last Quarter Recap

In Q1-2026, Arcutis reported an EPS of -$0.09, which was a larger loss than analysts expected. Despite this, the stock rose by 3.20% the following day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts have mixed expectations for the upcoming earnings report, with no specific estimates available. Investors will be looking for signs of improvement in profitability and revenue growth.

Bull Case

If Arcutis can show a significant reduction in losses or even a profit, it could boost investor confidence and lead to a strong stock performance.

Bear Case

Conversely, if the company reports larger losses than expected or fails to provide clear guidance, it could lead to a negative reaction from the market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS and how does it compare to previous quarters?

The EPS figure will be a key indicator of the company's financial health and could significantly influence investor sentiment.

What guidance or outlook will management provide for the next quarter?

Any forward-looking statements will be crucial for understanding the company's growth prospects and could impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Arcutis' potential for a turnaround given its recent history of beating EPS expectations despite losses. Investors might overlook the company's ability to provide a more optimistic outlook this quarter.

Supporting Evidence

Arcutis has an 88% EPS beat rate over the last eight quarters, suggesting a pattern of exceeding expectations.

The stock has shown resilience with positive reactions following earnings surprises, indicating investor confidence.

Options pricing suggests a significant move, which may reflect underlying investor sentiment not captured in consensus estimates.

Key Risk

If EPS comes in better than -$0.05, it could challenge the current negative sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether the company can show improvement in its financial metrics.

Bull Confirmed If

A reduction in EPS losses to below -$0.05 would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$0.15 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±18.36%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±18.4% while ARQT has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

62.0%

Calls (13K)P/C Ratio: 0.14Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcutis beats expectations and raises guidance, history suggests the stock could rise by around 2.7% on the following day.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience a muted reaction.

Miss

If the company misses expectations, history suggests a potential decline of around 3.2% the next day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or pipeline progress.
2Management's commentary on market conditions and competitive landscape.
3Details on cost management strategies and their impact on profitability.
4Insights into customer feedback and adoption rates for existing products.
5Any changes in regulatory environment affecting product approvals.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Arcutis Biotherapeutics, Inc. (ARQT) is a biotechnology company focused on developing innovative treatments for skin diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS indicates the company's profitability and is a key measure of its financial health.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and drive future profits.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ARQT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+19.67%

Avg Stock Reaction

+2.77%

Last Quarter Recap

In Q1-2026, Arcutis reported an EPS of -$0.09, which was a larger loss than analysts expected. Despite this, the stock rose by 3.20% the following day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts have mixed expectations for the upcoming earnings report, with no specific estimates available. Investors will be looking for signs of improvement in profitability and revenue growth.

Bull Case

If Arcutis can show a significant reduction in losses or even a profit, it could boost investor confidence and lead to a strong stock performance.

Bear Case

Conversely, if the company reports larger losses than expected or fails to provide clear guidance, it could lead to a negative reaction from the market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS and how does it compare to previous quarters?

The EPS figure will be a key indicator of the company's financial health and could significantly influence investor sentiment.

What guidance or outlook will management provide for the next quarter?

Any forward-looking statements will be crucial for understanding the company's growth prospects and could impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

Supporting Evidence

Arcutis has an 88% EPS beat rate over the last eight quarters, suggesting a pattern of exceeding expectations.

The stock has shown resilience with positive reactions following earnings surprises, indicating investor confidence.

Options pricing suggests a significant move, which may reflect underlying investor sentiment not captured in consensus estimates.

Key Risk

If EPS comes in better than -$0.05, it could challenge the current negative sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether the company can show improvement in its financial metrics.

Bull Confirmed If

A reduction in EPS losses to below -$0.05 would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$0.15 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±18.36%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±18.4% while ARQT has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

62.0%

Calls (13K)P/C Ratio: 0.14Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcutis beats expectations and raises guidance, history suggests the stock could rise by around 2.7% on the following day.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience a muted reaction.

Miss

If the company misses expectations, history suggests a potential decline of around 3.2% the next day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or pipeline progress.
2Management's commentary on market conditions and competitive landscape.
3Details on cost management strategies and their impact on profitability.
4Insights into customer feedback and adoption rates for existing products.
5Any changes in regulatory environment affecting product approvals.